Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.38 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.38 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.38 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3449600 | 0.85 | ALDH1A1 (0.40) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL8495470 | 0.81 | SLC6A4 (0.42) | SLC6A4SLC6A2KCNH2SLC6A3SIGMAR1 | |
| SCHEMBL3448664 | 0.80 | TDP1 (0.43) | SLC6A4SIGMAR1 | |
| SCHEMBL3450832 | 0.80 | HRH3 (0.42) | — | |
| SCHEMBL3450210 | 0.76 | NPC1 (0.40) | SLC6A4SLC6A2SLC6A3SIGMAR1HTR2C | |
| SCHEMBL3449794 | 0.73 | ALDH1A1 (0.45) | SLC6A4SLC6A2SIGMAR1BCHE | |
| SCHEMBL14198735 | 0.72 | SLC6A4 (0.56) | SLC6A4SLC6A2KCNH2SLC6A3SIGMAR1 | |
| SCHEMBL3451086 | 0.71 | SIGMAR1 (0.44) | SIGMAR1HTR2CHTR2B | |
| SCHEMBL3449404 | 0.71 | HRH4 (0.53) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL3448897 | 0.70 | CHRNB2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820673-B2 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-26 | — | — | US | disclosed |
| EP-1695961-A1 | UREA DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20020168337-A1 | Sustained-release preparation | TAKADA CHEMICAL INDUSTRIES LTD. | 2002-11-14 | — | — | US | disclosed |
| US-20020058622-A1 | Sustained-release preparation | IGARI YASUTAKA (JP) | 2002-05-16 | — | — | US | disclosed |
| US-6376461-B1 | WATER INSOLUBLE OR SLIGHTLY WATER SOLUBLE POLYVALENT METAL SALT OF A GROWTH HORMONE, AND A BIODEGRADABLE POLYMER; ENDOTHELIN ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-04-23 | — | — | US | disclosed |
| US-6251861-B1 | CYCLO(D-ASP-ASP(R1)-ASP-D-THG(2)-LEU-TRP) DISODIUM SALT, WHERE ASP(R1) IS AN ASPARTIC ACID BETA-4-PHENYLPIPERAZINE AMIDE RESIDUE AND THG(2) IS 2-(2-THIENYL)GLYCINE; ANTI-ENDOTHELIN ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| EP-0815870-A2 | Composition for prohylaxis or treatment of cerebral infarction | Takeda Chemical Industries, Ltd. (JP) | 1998-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020168337-A1 | Sustained-release preparation | EDNRA, EDNRB, ORAI1 | SLC6A4 560/4885SLC6A2 162/4885KCNH2 695/4885 |
| US-20020058622-A1 | Sustained-release preparation | EDNRA, EDNRB, ORAI1 | SLC6A4 560/4885SLC6A2 162/4885KCNH2 695/4885 |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | F2, URB2, F12 | SLC6A4 3725/4885SLC6A2 2189/4885KCNH2 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.